Test Price
750 AED✅ Home Collection Available
Chronic Lymphocytic Leukemia (CLL) Mutations Detection Panel 1 Test in Dubai
Executive Summary & Core Metrics
High-Throughput Molecular Profiling for Personalized CLL Management
- Diagnostic Sensitivity: 99.9% analytical sensitivity and specificity via ISO 15189 accredited PCR and MLPA processing protocols.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Dedicated telephonic post-test consultation for result interpretation and clinical decision support.
- Insurance Facilitation: Direct billing verification and insurance pre-approval coordination via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The Chronic Lymphocytic Leukemia (CLL) Mutations Detection Panel 1 is a high-resolution molecular diagnostic assay designed to identify critical genetic aberrations influencing CLL prognosis and therapeutic response. Utilizing Polymerase Chain Reaction (PCR) and Multiplex Ligation-dependent Probe Amplification (MLPA), this panel precisely detects submicroscopic deletions and mutations in key genes such as TP53 (17p deletion), ATM (11q deletion), and other clinically significant loci. This genomic intelligence empowers hematologists and oncologists to stratify risk accurately, predict treatment outcomes, and select targeted therapies, including BTK inhibitors and BCL-2 antagonists, in full compliance with UAE and international oncology guidelines.
| Feature | Our CLL Mutations Panel 1 | Conventional FISH Panel |
|---|---|---|
| Methodology | PCR + MLPA (Multiplex Ligation-dependent Probe Amplification) | Fluorescence In Situ Hybridization (FISH) |
| Precision & Resolution | Detects submicroscopic deletions with high sensitivity across multiple genes | Limited resolution; may miss small deletions or mutations |
| Turnaround Time | Results within 5 days (Sample Monday, Report Saturday) | 7-10 days typical |
| Clinical Utility | Directly guides targeted therapy selection and risk stratification | Prognostic, but identifies fewer actionable mutations |
Physician Insight & Safety Protocols
“As a Specialist in Diagnostic Radiology deeply involved in the multidisciplinary management of hematological malignancies, I recognize the indispensable role of comprehensive genomic profiling in Chronic Lymphocytic Leukemia. This molecular panel provides detailed data on critical genetic drivers such as TP53 and ATM, which, when integrated with clinical staging and imaging findings, enables precise risk stratification and truly personalized therapeutic planning. It is essential that patients review these results in detail with their treating hematologist.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Medication & Clinical Advisory
Do not discontinue or modify prescribed anticoagulant, anti-leukemic, or supportive care therapy without direct consultation with your managing physician. This test provides diagnostic and prognostic genetic information to support clinical decision-making and does not replace the expertise of your healthcare provider.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Inappropriately stored, hemolyzed, or clotted blood samples; samples from patients who have received a blood transfusion in the preceding 3 weeks; test is not indicated for acute leukemia or emergency diagnostic settings.
- Emergency Red Flags: Seek immediate emergency department evaluation if you experience severe bleeding, sudden high fever, confusion, rapid onset of profound fatigue, or signs of tumor lysis syndrome (nausea, vomiting, irregular heartbeat, muscle cramps).
Patient FAQ & Clinical Guidance
1. What specific mutations does the CLL Panel 1 test detect?
A: This panel detects clinically significant deletions and mutations in genes such as TP53 (17p deletion), ATM (11q deletion), and other key loci influencing CLL progression and drug resistance. The test requires 4 mL of whole blood collected in an EDTA tube, which must be shipped under temperature-controlled refrigerated conditions to ensure RNA/DNA integrity.
2. How should I prepare for the blood collection procedure?
A: Fasting is not required. However, patients should avoid heavy physical exertion and alcohol consumption for 24 hours prior to sampling. A duly completed Genomics Clinical Information Requisition Form (Form 20) is mandatory. Our certified mobile phlebotomist will conduct the draw using strict cold-chain transport protocols to maintain specimen stability.
3. What is the turnaround time and can I use my health insurance?
A: For samples collected by Monday 11 AM, results are reported by Saturday. Direct billing is available; please contact +971 54 548 8731 via WhatsApp with your insurance policy details and a valid referral letter to confirm coverage and obtain pre-authorization before booking.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE strictly operates within the UAE's comprehensive legislative framework for personal data and health information governance:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): Governing the processing of personal data and ensuring patient privacy rights.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: Regulating the handling and security of electronic health records and clinical data.
- Federal Decree-Law No. 4 of 2016 on Medical Liability: Establishing the legal framework for clinical practice standards and patient safety.
Our DHA Facility License Number 1143 (Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE) guarantees that all genomic and clinical data processing adheres to the highest standards of regulatory compliance and patient confidentiality.
Clinical & Logistical Metadata
| Test Name | Chronic Lymphocytic Leukemia (CLL) Mutations Detection Panel 1 |
| Price (AED) | 750 |
| Turnaround Time | 5 Days (Sample Mon, Report Sat) |
| Sample Type / Matrix | Whole Blood (EDTA Tube) |
| Methodology Used | PCR + MLPA (Multiplex Ligation-dependent Probe Amplification) |
| ICD-10-CM Code | C91.1 |
| LOINC Code | 101467-8 |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians